

Treatment Of HR + Adjuvant Breast Cancer

Reference Number: RDF1095-22

Date of Response: 13/12/2022

Further to your Freedom of Information Act request, please find the Trust's response(s) below:

- 1) Over the latest 12 months of data that you have access to, how many patients who were diagnosed with HR+ adjuvant breast cancer received trastuzumab monotherapy?

The Trust holds this information.

At the Eastern area of the Trust, the number of patients who have received trastuzumab monotherapy in the last 12 months with a diagnosis of HR+Adjuvant Breast Cancer is 37.

Please note this is not the number of patients diagnosed in the last 12 months only the number of people with this diagnosis who have received this medication in the last 12 months.

For the Northern area of the Trust, the number of patients who have received trastuzumab monotherapy in the last 12 months with a diagnosis of HR+Adjuvant Breast Cancer is 35.

Please note this is not the number of patients diagnosed in the last 12 months only the number of people with this diagnosis who have received this medication in the last 12 months.

